Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca is pushing further into cell and gene therapy with a $2.2 billion potential deal with Cellectis covering up to 10 candidates. The pharma giant will…
AstraZeneca and Cellectis announced a research collaboration to design novel cell and gene therapy candidates leveraging Cellectis' TALEN gene-editing…
Cellectis FY2024 results: three programs are in initial development under the AZ JRCA — one allogeneic CAR-T for hematological malignancies, one allogeneic…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
AstraZeneca entered a research collaboration and equity investment with Cellectis (Nasdaq/Euronext: CLLS) on November 28, 2023 to design up to 10 cell and gene therapy candidates across oncology, immunology and rare disease using Cellectis' TALEN gene-editing platform and manufacturing capabilities. AstraZeneca paid $105M initially ($25M upfront cash plus an $80M equity investment at $5.00/share, ~22% stake), with each of the up to 10 candidate products eligible for an IND option fee plus development, regulatory and sales milestones ranging from $70M up to $220M per product, plus tiered royalties. AstraZeneca subsequently completed an additional $140M equity investment at $5.00/share on May 6, 2024 (after French Ministry of Economy clearance and Cellectis shareholder approval), lifting its stake to approximately 44% of share capital / 30% of voting rights and adding two AstraZeneca directors to the Cellectis board. By December 31, 2024 three programs were in initial development under the joint research collaboration agreement (two allogeneic CAR-T candidates for hematological malignancies and solid tumors, and one in vivo gene therapy for a genetic disorder), with $47M paid to Cellectis to date ($25M upfront plus $22M in development milestones). The collaboration remained active as of January 2026. AstraZeneca's equity backing extends Cellectis' cash runway into mid-2027.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Cellectis SA (this deal) | 2023 | $605M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2023 deals · AstraZeneca PLC deals · Immunology deals